FDA Expands VYVGART Approval to All Adult gMG Patients, Significantly Broadening ARGENX's Market
Summary
ARGENX SE announced a significant regulatory win with the U.S. FDA's approval to expand the label for its key drugs, VYVGART and VYVGART Hytrulo, to include all adult patients living with generalized myasthenia gravis (gMG). This expansion, based on positive Phase 3 ADAPT SERON study data, means the drugs are now approved for all serotypes of gMG, including those previously underserved. This materially increases the total addressable market for ARGENX's flagship product, enhancing its revenue potential and solidifying its leadership in gMG treatment. The news follows recent strong Q1 2026 sales of $1.3 billion, indicating robust commercial momentum. Traders will be closely monitoring the company's updated sales forecasts and market penetration as a result of this broader indication.
At the time of this announcement, ARGX was trading at $790.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $48.7B. The 52-week trading range was $510.06 to $934.62. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.